| Votrient (pazopanib) / Novartis, BeiGene |
2011-006085-40: Evaluation of predictive markers for toxicity and efficacy in patients with metastatic clear cell renal cell carcinoma treated by anti VEGF therapy. |
|
|
| Ongoing | 4 | 90 | Europe | Sutent, Film-coated tablet, Capsule, hard, Votrient, Sutent | Cliniques Universitaires Saint Luc, Pfizer | Metastatic clear cell renal cell carcinoma, Metastatic renal cancer, Diseases [C] - Cancer [C04] | | | | |
2012-001415-23: Clinical study to evaluate the effect of sunitinib ans pazopanib blood levels over time and other parameters in patients with kidney cell cancer. |
|
|
| Ongoing | 4 | 100 | Europe | Sutent, Votrient, Sutent, Votrient | Central European Society for Anticancer Drug Research - EWIV, CESAR | Metastasized renal cell carcinoma | | | | |
2016-005252-21: Increasing the amount of pazopanib in the blood by splitting intake moments Verhogen van de hoeveelheid pazopanib in het bloed door het spreiden van inname momenten |
|
|
| Ongoing | 4 | 10 | Europe | Tablet, Votrient | Netherlands Cancer Institute, Netherlands Cancer Institute | Patients for whom pazopanib is considered standard care (advanced renal cell carcinoma and advanced soft-tissue sarcoma). Patiënten voor wie behandeling met pazopanib standaard zorg is (gevorderd renaal cel carcinoom of gevorderd weke delen sarcoom)., Patients with advanced renal cell carcinoma or advanced soft-tissue sarcoma Patiënten met nierkanker of weke delen kanker, Diseases [C] - Cancer [C04] | | | | |
2018-003954-26: CYP3A4*22 genotype-guided dosing of TKIs in cancer patients: a new way of personalized therapy Op basis van CYP3A4*22 genotype doseren van tyrosine-kinase remmers bij patiënten met kanker: een nieuwe manier van gepersonaliseerde therapie. |
|
|
| Not yet recruiting | 4 | 198 | Europe | Film-coated tablet, Capsule, hard, Coated tablet, Tablet, Cabozantinib/Cabometyx, Cobimetinib/Cotellic, Dabrafenib/Tafinlar, Dasatinib/Sprycel, Erlotinib/Tarceva, Everolimus/Afinitor/Votubia, Imatinib, Lapatinib/Tyverb, Nilotinib/Tasigna, Olaparib/Lynparza, Palbociclib/Ibrance, Ponatinib/Iclusig, Regorafenib/Stivarga, Ruxolitinib/Jakavi, Sunitinib/Sutent, Pazopanib/Votrient, Cabozantinib/Cometriq, Olaparib?Lynparza, Brigatinib - Alunbrig, Encorafenib - Braftovi, Osimertinib/Tagrisso | Erasmus MC Cancer Institute, Erasmus MC | Patients diagnosed with a neoplasm and treated with a tyrosine kinase inhibitor which is mainly metabolised by CYP3A4. Patienten gediagnosticeerd met een maligniteit en behandeld met een tyrosine kinase inhibitor welke voornamelijk wordt gemetaboliseerd door CYP3A4., Patients diagnosed with cancer and treated with a TKI. Patienten gediagnosticeerd met kanker en behandeld met een TKI., Diseases [C] - Cancer [C04] | | | | |
ChiCTR-OPB-17013321: Study of Efficacy and Safety of Presurgical Pazopanib Therapy in Renal Cell Carcinoma with Inferior Vena Cava Tumor Thrombus: a clinical multicentric prospective study |
|
|
| Recruiting | 4 | 29 | | pazopanib targeted treatment | Chinese PLA General Hospital; Chinese PLA General Hospital, No | Renal Cell Carcinoma with Inferior Vena Cava Tumor Thrombus | | | | |
ChiCTR2100044810: A controlled clinical study the combination of first-line immunotherapy and targeted therapy for advanced sarcomatoid renal cell carcinoma |
|
|
| Recruiting | 4 | 40 | | camrelizumab plus Pazopanib Tablets ;Pazopanib Tablets | Qilu Hospital of Shandong University; Qilu Hospital of Shandong University, Partially self-financing | Advanced sarcomatoid renal cell carcinoma | | | | |
| Not yet recruiting | 4 | 30 | Europe | Olaparib, Lynparza, Lenvatinib, Lenvima, Sunitinib, Sutent, Palbociclib, Ibrance, Pazopanib, Votrient | University Medical Center Groningen | Renal Cell Carcinoma, Ovarian Carcinoma, Thyroid Carcinoma, Breast Carcinoma, Endometrium Carcinoma | 03/25 | 03/25 | | |
